BioStem Technologies, Inc. announces that the Centers for Medicare and Medicaid Services (“CMS”) has published a new code pursuant to the Company’s application for Healthcare Common Procedure Coding System (“HCPCS”) “Q” codes. The Company initially filed an application in July of 2020 to have CMS establish a new HCPCS Q code for VENDAJE® and has now received a favorable decision in July of 2021.
BioStem Technologies today announced that it has appointed three key members to its scientific advisory board (SAB). The board, chaired by Kenneth Warrington, Ph.D., welcomes new members Jeffrey Harrison, Ph.D., Daniel Shelly, Ph.D., and Shaun Opie, Ph.D.
BioStem announced that it has received the TRIP (TRG Rapid Inquiry Program) response from the FDA’s Tissue Reference Group (TRG) for the Company’s amniotic membrane allograft, VENDAJE™
BioStem Technologies, Inc. announced it engaged D. Brooks and Associates CPA's, P.A. as the Company’s PCAOB registered certified public accounting firm for the 2020 and 2019 fiscal years.
